{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T23:03:02Z","timestamp":1780095782667,"version":"3.54.0"},"reference-count":19,"publisher":"Georg Thieme Verlag KG","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Was ist neu?<\/jats:title>\n                  <jats:p>Seit Ende 2025 steht uns endlich eine deutschsprachige Leitlinie zur Diagnostik und Therapie der systemischen Sklerose zur Verf\u00fcgung. Dies ist besonders wichtig, da die Erkrankung h\u00e4ufig zu sp\u00e4t erkannt und dadurch verz\u00f6gert therapiert wird. Einfache Diagnostiken wie Autoantik\u00f6rperdiagnostik und Kapillarmikroskopie bei atypischer Raynaud-Symptomatik helfen eine fr\u00fchere (Verdachts-) Diagnose zu stellen.<\/jats:p>\n                  <jats:p>Die SSc geht mit negativen Ver\u00e4nderungen wichtiger Organe einher. Die Fachgesellschaften empfehlen daher neben der regelm\u00e4\u00dfigen Auskultation und Lungenfunktionspr\u00fcfung auch fr\u00fchzeitig ein CT-Thorax zu erg\u00e4nzen. Aufgrund h\u00e4ufiger kardialer Manifestationen geh\u00f6rt auch die regelm\u00e4\u00dfige kardiologische Diagnostik dazu. Ein besonders hohes renales Risiko besteht beim Nachweis von RNA-POL-III-AK beim Einsatz von Glukokortikosteroiden.<\/jats:p>\n                  <jats:p>Neue Risiko-Scores wurden erarbeitet, um Patient*innen mit einem raschen Progress fr\u00fch zu identifizieren und an entsprechende Zentren zu verweisen. Den neuesten und relativ einfachen Score stellt der sogenannte RESIST-Score dar.<\/jats:p>\n                  <jats:p>In Deutschland gibt es trotz der Seltenheit der Erkrankung einige spezialisierte Zentren, an die verwiesen werden sollte. Therapeutisch ist die Behandlung zwar immer noch eingeschr\u00e4nkt, allerdings gibt es Therapieoptionen und es laufen auch einige Studien mit vielversprechenden neuen Substanzen wie z.B. Nerandomilast, Anifrolumab oder Belimumab aber auch zu CAR-T-Zell-Therapie.<\/jats:p>","DOI":"10.1055\/a-2676-2759","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T22:38:29Z","timestamp":1780094309000},"page":"645-651","source":"Crossref","is-referenced-by-count":0,"title":["Systemische Sklerose im Fokus"],"prefix":"10.1055","volume":"151","author":[{"given":"J\u00f6rg","family":"Henes","sequence":"additional","affiliation":[{"name":"University of Tubingen, Baden-W\u00fcrttemberg, Germany","place":["Tubingen"],"department":["Rheumatologie"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Christin","family":"Pecher","sequence":"additional","affiliation":[{"name":"University of Tubingen, Baden-W\u00fcrttemberg, Germany","place":["Tubingen"],"department":["Rheumatologie"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"15002","DOI":"10.1038\/nrdp.2015.2","article-title":"Systemic sclerosis","volume":"1","author":"Y Allanore","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.3899\/jrheum.100245","article-title":"Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies","volume":"37","author":"J Avouac","year":"2010","journal-title":"J Rheumatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1136\/annrheumdis-2017-211448","article-title":"Mapping and predicting mortality from systemic sclerosis","volume":"76","author":"M Elhai","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"09","key":"ref4","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s00393-025-01646-8","article-title":"Annual report 2025 from the National Database of the Regional Collaborative Rheumatology Centers in Germany","volume":"84","author":"K Albrecht","year":"2025","journal-title":"Z Rheumatol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1136\/ard.2006.066068","article-title":"Changes in causes of death in systemic sclerosis, 1972\u20132002","volume":"66","author":"VD Steen","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/ard-2024-226430","article-title":"EULAR recommendations for the treatment of systemic sclerosis: 2023 update","volume":"84","author":"F Del Galdo","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"S 4","key":"ref7","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00393-025-01696-y","article-title":"S2k guidelines on diagnostics and treatment of systemic sclerosis : Full version","volume":"84","author":"JC Henes","year":"2025","journal-title":"Z Rheumatol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.1093\/rheumatology\/keae394","article-title":"The 2024 British Society for Rheumatology guideline for management of systemic sclerosis","volume":"63","author":"CP Denton","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative","volume":"72","author":"F den Hoogen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3899\/jrheum.180582","article-title":"Scleroderma Renal Crisis: Risk Factors for an Increasingly Rare Organ Complication","volume":"47","author":"P Moinzadeh","year":"2020","journal-title":"J Rheumatol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13075-020-2141-2","article-title":"ACE inhibitors in SSc patients display a risk factor for scleroderma renal crisis-a EUSTAR analysis","volume":"22","author":"L Butikofer","year":"2020","journal-title":"Arthritis Res Ther"},{"issue":"04","key":"ref12","doi-asserted-by":"publisher","first-page":"52","DOI":"10.55563\/clinexprheumatol\/e9n3n9","article-title":"Erectile function and connective tissue diseases. Prevalence of erectile dysfunction in German men with systemic sclerosis compared to other connective tissue diseases and healthy subjects","volume":"39","author":"SM Krittian","year":"2021","journal-title":"Clin Exp Rheumatol"},{"issue":"03","key":"ref13","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3390\/sclerosis3030026","article-title":"Systemic Sclerosis in Women \u2013 Impact on Sexuality, Fertility, Pregnancy, and Menopause","volume":"3","author":"A-C Pecher","year":"2025","journal-title":"Sclerosis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2026.01.016","article-title":"Risk Score for Early Mortality to stratify for Intensive SSc Therapy in the EUSTAR network: The RESIST score","author":"AC Pecher","year":"2026","journal-title":"Ann Rheum Dis"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1136\/ard.2010.130658","article-title":"Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial","volume":"70","author":"M Matucci-Cerinic","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1056\/NEJMc1910735","article-title":"Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. Reply","volume":"381","author":"O Distler","year":"2019","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00879-2022","article-title":"2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"61","author":"M Humbert","year":"2023","journal-title":"Eur Respir J"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1016\/S2665-9913(24)00282-0","article-title":"CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series","volume":"7","author":"J Auth","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ero.2025.03.005","article-title":"CD19-targeting CAR T cell therapy in 5 patients with systemic sclerosis unsuitable for autologous stem cell transplantation","author":"AH Pecher","year":"2025","journal-title":"EULAR Rheumatology Open"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2676-2759.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T22:38:38Z","timestamp":1780094318000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2676-2759"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":19,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2026,5,29]]},"published-print":{"date-parts":[[2026,6]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2676-2759","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]}}}